Prevalence of biotin supplement usage in outpatients and plasma biotin concentrations in patients presenting to the emergency department

Brooke M. Katzman, Alan J. Lueke, Leslie J. Donato, Allan S Jaffe, Nikola A. Baumann

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Several cases of biotin interference with laboratory testing have been reported in the literature. However, there are no publications discussing the extent of biotin use or plasma concentrations observed among the patient population. The objective of this study was to determine the prevalence of biotin consumption using two distinct methods: surveying the outpatient population using a questionnaire and quantifying biotin in plasma samples collected from patients presenting to the Emergency Department (ED). Methods: Survey questionnaires (n = 4000) were distributed to Mayo Clinic outpatients over one week (July 10–14, 2017). Biotin was quantified in residual waste plasma samples collected for physician-ordered electrolyte panels from patients presenting to the ED (March 6–12, 2017 and March 26–April 4, 2017, n = 1442 unique patient samples). Results: 1944 patients (972 female, 963 male, 9 no answer) with a median (interquartile range) age of 62 (49–72) years returned completed questionnaires (48.6%). From the completed surveys, 7.7% (95% CI, 6.6–8.9%) indicated biotin use. Quantitation of biotin in plasma samples from ED patients (n = 1442) revealed that 7.4% (95% CI, 6.2–8.9%) had concentrations at or above the lowest known threshold (10 ng/mL) for biotin interference in Roche Diagnostics immunoassay tests. Conclusions: According to our survey results, reported use of biotin was common. The range of biotin concentrations in ED patient samples highlights the magnitude of the biotin interference problem and identifies a population at risk for potential harm. These findings should guide laboratorians and clinicians in developing effective strategies to mitigate safety risks and in assessing biotin usage trends within their own patient populations.

Original languageEnglish (US)
Pages (from-to)11-16
Number of pages6
JournalClinical Biochemistry
Volume60
DOIs
StatePublished - Sep 1 2018

Fingerprint

Biotin
Hospital Emergency Service
Outpatients
Plasmas
Population
Surveying
Ambulatory Care Facilities
Immunoassay
Routine Diagnostic Tests
Electrolytes
Publications
Surveys and Questionnaires
Physicians
Safety

Keywords

  • Biotin
  • Immunoassay interference
  • Prevalence
  • Streptavidin

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Prevalence of biotin supplement usage in outpatients and plasma biotin concentrations in patients presenting to the emergency department. / Katzman, Brooke M.; Lueke, Alan J.; Donato, Leslie J.; Jaffe, Allan S; Baumann, Nikola A.

In: Clinical Biochemistry, Vol. 60, 01.09.2018, p. 11-16.

Research output: Contribution to journalArticle

@article{b94face298ea4efdb877b8676abeede5,
title = "Prevalence of biotin supplement usage in outpatients and plasma biotin concentrations in patients presenting to the emergency department",
abstract = "Background: Several cases of biotin interference with laboratory testing have been reported in the literature. However, there are no publications discussing the extent of biotin use or plasma concentrations observed among the patient population. The objective of this study was to determine the prevalence of biotin consumption using two distinct methods: surveying the outpatient population using a questionnaire and quantifying biotin in plasma samples collected from patients presenting to the Emergency Department (ED). Methods: Survey questionnaires (n = 4000) were distributed to Mayo Clinic outpatients over one week (July 10–14, 2017). Biotin was quantified in residual waste plasma samples collected for physician-ordered electrolyte panels from patients presenting to the ED (March 6–12, 2017 and March 26–April 4, 2017, n = 1442 unique patient samples). Results: 1944 patients (972 female, 963 male, 9 no answer) with a median (interquartile range) age of 62 (49–72) years returned completed questionnaires (48.6{\%}). From the completed surveys, 7.7{\%} (95{\%} CI, 6.6–8.9{\%}) indicated biotin use. Quantitation of biotin in plasma samples from ED patients (n = 1442) revealed that 7.4{\%} (95{\%} CI, 6.2–8.9{\%}) had concentrations at or above the lowest known threshold (10 ng/mL) for biotin interference in Roche Diagnostics immunoassay tests. Conclusions: According to our survey results, reported use of biotin was common. The range of biotin concentrations in ED patient samples highlights the magnitude of the biotin interference problem and identifies a population at risk for potential harm. These findings should guide laboratorians and clinicians in developing effective strategies to mitigate safety risks and in assessing biotin usage trends within their own patient populations.",
keywords = "Biotin, Immunoassay interference, Prevalence, Streptavidin",
author = "Katzman, {Brooke M.} and Lueke, {Alan J.} and Donato, {Leslie J.} and Jaffe, {Allan S} and Baumann, {Nikola A.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.clinbiochem.2018.07.004",
language = "English (US)",
volume = "60",
pages = "11--16",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Prevalence of biotin supplement usage in outpatients and plasma biotin concentrations in patients presenting to the emergency department

AU - Katzman, Brooke M.

AU - Lueke, Alan J.

AU - Donato, Leslie J.

AU - Jaffe, Allan S

AU - Baumann, Nikola A.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background: Several cases of biotin interference with laboratory testing have been reported in the literature. However, there are no publications discussing the extent of biotin use or plasma concentrations observed among the patient population. The objective of this study was to determine the prevalence of biotin consumption using two distinct methods: surveying the outpatient population using a questionnaire and quantifying biotin in plasma samples collected from patients presenting to the Emergency Department (ED). Methods: Survey questionnaires (n = 4000) were distributed to Mayo Clinic outpatients over one week (July 10–14, 2017). Biotin was quantified in residual waste plasma samples collected for physician-ordered electrolyte panels from patients presenting to the ED (March 6–12, 2017 and March 26–April 4, 2017, n = 1442 unique patient samples). Results: 1944 patients (972 female, 963 male, 9 no answer) with a median (interquartile range) age of 62 (49–72) years returned completed questionnaires (48.6%). From the completed surveys, 7.7% (95% CI, 6.6–8.9%) indicated biotin use. Quantitation of biotin in plasma samples from ED patients (n = 1442) revealed that 7.4% (95% CI, 6.2–8.9%) had concentrations at or above the lowest known threshold (10 ng/mL) for biotin interference in Roche Diagnostics immunoassay tests. Conclusions: According to our survey results, reported use of biotin was common. The range of biotin concentrations in ED patient samples highlights the magnitude of the biotin interference problem and identifies a population at risk for potential harm. These findings should guide laboratorians and clinicians in developing effective strategies to mitigate safety risks and in assessing biotin usage trends within their own patient populations.

AB - Background: Several cases of biotin interference with laboratory testing have been reported in the literature. However, there are no publications discussing the extent of biotin use or plasma concentrations observed among the patient population. The objective of this study was to determine the prevalence of biotin consumption using two distinct methods: surveying the outpatient population using a questionnaire and quantifying biotin in plasma samples collected from patients presenting to the Emergency Department (ED). Methods: Survey questionnaires (n = 4000) were distributed to Mayo Clinic outpatients over one week (July 10–14, 2017). Biotin was quantified in residual waste plasma samples collected for physician-ordered electrolyte panels from patients presenting to the ED (March 6–12, 2017 and March 26–April 4, 2017, n = 1442 unique patient samples). Results: 1944 patients (972 female, 963 male, 9 no answer) with a median (interquartile range) age of 62 (49–72) years returned completed questionnaires (48.6%). From the completed surveys, 7.7% (95% CI, 6.6–8.9%) indicated biotin use. Quantitation of biotin in plasma samples from ED patients (n = 1442) revealed that 7.4% (95% CI, 6.2–8.9%) had concentrations at or above the lowest known threshold (10 ng/mL) for biotin interference in Roche Diagnostics immunoassay tests. Conclusions: According to our survey results, reported use of biotin was common. The range of biotin concentrations in ED patient samples highlights the magnitude of the biotin interference problem and identifies a population at risk for potential harm. These findings should guide laboratorians and clinicians in developing effective strategies to mitigate safety risks and in assessing biotin usage trends within their own patient populations.

KW - Biotin

KW - Immunoassay interference

KW - Prevalence

KW - Streptavidin

UR - http://www.scopus.com/inward/record.url?scp=85052753150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052753150&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2018.07.004

DO - 10.1016/j.clinbiochem.2018.07.004

M3 - Article

VL - 60

SP - 11

EP - 16

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

ER -